The concordance between germline BRCA1/2 pathogenic variants detected in germline and tumour DNA was 94% (44/47) and 100% (28/28) using our in-house tumour BRCA1/2 assay and Myriad’s myChoice® CDx, respectively. The gene discussed is BRCA1; the disease is neoplasm.